Enovis Corp (LTS:0I1B)
$ 48.35 -0.10705 (-0.22%) Market Cap: 2.73 Bil Enterprise Value: 4.11 Bil PE Ratio: 0 PB Ratio: 0.82 GF Score: 68/100

Enovis Corp at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 03:30PM GMT
Release Date Price: $60.25
Kyle William Rose
Canaccord Genuity Corp., Research Division - Senior Analyst

Good morning, everyone, and thank you for joining us. My name is Kyle Rose. I am one of the medical technology analysts here at Canaccord Genuity. I appreciate you all joining us at our Annual Global Growth Conference. It's a pleasure to see everyone again in person.

Very excited to be joined this morning by Enovis. They're a differentiated medical device company focused on products that really span the entire continuum of the orthopedic and musculoskeletal practice, all the way from injury prevention through to repair and recovery, so definitely a differentiated asset to be paying attention to.

With me today, we've got, from Enovis, we have Ben Berry, he's the CFO; as well as the VP of IR, Derek Leckow. Thank you both for joining me. We're going to jump into a bit of a presentation and then a fireside chat at the second half year. But before I begin and before I hand it over, I need to make sure any disclosures, if and where applicable, you can find them on our firm website, conference website. And then we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot